Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Accumulated Expenses (2016 - 2026)

Cytosorbents filings provide 16 years of Accumulated Expenses readings, the most recent being $6.3 million for Q4 2025.

  • On a quarterly basis, Accumulated Expenses rose 4.43% to $6.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $6.3 million, a 4.43% increase, with the full-year FY2025 number at $6.3 million, up 4.43% from a year prior.
  • Accumulated Expenses hit $6.3 million in Q4 2025 for Cytosorbents, down from $6.6 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $10.3 million in Q4 2021 to a low of $5556.0 in Q4 2022.
  • Median Accumulated Expenses over the past 5 years was $6.8 million (2023), compared with a mean of $6.5 million.
  • Biggest five-year swings in Accumulated Expenses: tumbled 99.95% in 2022 and later soared 60088.62% in 2023.
  • Cytosorbents' Accumulated Expenses stood at $10.3 million in 2021, then tumbled by 99.95% to $5556.0 in 2022, then soared by 60088.62% to $3.3 million in 2023, then skyrocketed by 80.38% to $6.0 million in 2024, then increased by 4.43% to $6.3 million in 2025.
  • The last three reported values for Accumulated Expenses were $6.3 million (Q4 2025), $6.6 million (Q3 2025), and $6.0 million (Q2 2025) per Business Quant data.